GuruPSonpavdeMD

Genitourinary Oncology

GU Oncology & Phase I Clinical Trial Director AdventHealth Cancer Institute Professor, University of Central Florida Orlando, FL, USA

Join to view full profile

Dr. Sonpavde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sonpavde's full profile

Already have an account?

Office
AdventHealth Cancer Institute
2501 N Orange Ave, Ste 681
Orlando, FL 32804
Phone+1 407-303-2024

Fax+1 407-303-2038
Is this information wrong?

Summary

Dr. Guru Sonpavde is an oncologist in Orlando, FL. He received his medical degree from Christian Medical College Vellore and has been in practice 27 years. He specializes in genitourinary oncology and is experienced in Phase I clinical trials and prostate cancer, urologic oncology, bladder cancer, kidney cancer and urinary tract cancer. He has more than ~500 publications.

Current and Emerging Agents to Treat Advanced Bladder Cancer

A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelia

A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelial Carcinoma

Immunotherapy Outcomes in Pure vs Mixed Urothelial Carcinoma Histology

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998
Nassau University Medical CenterResidency, Internal Medicine, 1992 - 1995
Christian Medical College VelloreClass of 1990

Certifications & Licensure

CT State Medical License Current
FL State Medical License 2022 - 2026
MA State Medical License 2017 - 2024
RI State Medical License 2020 - 2020
AL State Medical License Active through 2017
TX State Medical License 2003 - 2013
AZ State Medical License 2001 - 2003
TN State Medical License 1999 - 2002
IN State Medical License 1995 - 1999
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Vidaza to Restore Hormone Thx Prostate Start of enrollment: 2006 Apr 01
Completed
Phase 2
Phase II Sunitinib Prog Met AIPC Start of enrollment: 2007 Mar 01
Completed
Phase 2
Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
Completed
Phase 2
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal Start of enrollment: 2011 Apr 01
Terminated
Phase 2
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Unknown status
Phase 1, Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 1
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 2
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 3
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment Start of enrollment: 2014 Apr 01
Completed
Phase 2
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Start of enrollment: 2014 Aug 28
Completed
Phase 2
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2015 May 01
Terminated
Phase 1
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27
Completed
Phase 2
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Start of enrollment: 2015 May 01
Completed
Phase 2
Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Start of enrollment: 2016 Oct 01
Terminated
Phase 2
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Start of enrollment: 2017 May 23
Withdrawn
Phase 2
Phase I Trial of PACE for Metastatic Prostate Cancer Start of enrollment: 2018 May 09
Withdrawn
Phase 1
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Start of enrollment: 2019 Feb 20
Completed
Phase 1
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2021 Jan 21
Active, not recruiting
Phase 2
Sacituzumab Govitecan Plus EV in Metastatic UC Start of enrollment: 2021 May 20
Active, not recruiting
Phase 1
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients Start of enrollment: 2021 Apr 30
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Sumanta K Pal, Petros Grivas, Shilpa Gupta, Nazli Dizman, Zeynep Zengin, Begona P Valderrama, Alejo Rodriguez-Vida, Florian Roghmann, Elena Sevillano Fernandez, Surena...> ;European Urology. 2024 Apr 4
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
Amin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishank...> ;Journal for Immunotherapy of Cancer. 2024 Mar 5
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
Rosenberg, J., Mamtani, R., Sonpavde, G., Loriot, Y., Duran, I., Lee, J., Matsubara, N., Vulsteke, C., Castellano, D., Sridhar, S., Pappot, H., Gurney, H., Bedke, J., ...> ;European Urology. 2024 Feb 27
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
Ravi, P., Freeman, D., Thomas, J., Ravi, A., Mantia, C., McGregor, B., Berchuck, J., Epstein, I., Budde, P., Ahangarian Abhari, B., Rupieper, E., Gajewski, J., Schuber...> ;Journal for Immunotherapy of Cancer. 2024 Feb 2
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
Petrylak, D., Eigl, B., George, S., Heath, E., Hotte, S., Chism, D., Nabell, L., Picus, J., Cheng, S., Appleman, L., Sonpavde, G., Morgans, A., Pourhosseini, P., Wu, R...> ;Clinical Cancer Research. 2024 Jan 5
Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.
Carlos Riveros, Sanjana Ranganathan, Waqar Haque, Emily Huang, Jiaqiong Xu, Girish S Kulkarni, Michael Geng, Maryam Anis, Taliah Muhammad, Keith Syson Chan, Andrew Far...> ;Canadian Urological Association Journal = Journal De L'association Des Urologues Du Canada. 2024 Feb 1
Total Margin Control Is Superior to Traditional Margin Assessment for Treatment of Low-Stage Penile Squamous Cell Carcinoma.
Katie A O'Connell, Jacob L Thomas, Fadi Murad, Guohai Zhou, Guru P Sonpavde, Matthew Mossanen, Timothy N Clinton, Antonio Ji-Xu, Kristina Alton, Philippe E Spiess, Ant...> ;The Journal of Urology. 2024 Jan 1
Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.
Huma Q Rana, Jill E Stopfer, Michelle Weitz, Lindsay Kipnis, Diane R Koeller, Samantha Culver, Joanna Mercado, Rebecca Sue Gelman, Meghan Underhill-Blazey, Bradley A M...> ;JCO Oncology Practice. 2023 Nov 1
6 citations
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
Talal El Zarif, Amin H Nassar, Gregory R Pond, Tony Zibo Zhuang, Viraj Master, Bassel Nazha, Scot Niglio, Nicholas Simon, Andrew W Hahn, Curtis A Pettaway, Shi-Ming Tu...> ;Journal of the National Cancer Institute. 2023 Dec 6
Muscle invasive bladder cancer: where is the field headed?
Pooja Ghatalia, Jasmeet Kaur, Guru Sonpavde> ;Expert Opinion on Biological Therapy. 2023 Jul 21
7 citations
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in Pe...
Dobbs, R. W., Talal El Zarif, Amin H Nassar, Elio Adib, Bailey G Fitzgerald, Jiaming Huang, Tarek H Mouhieddine, Paul G Rubinstein, Taylor Nonato, Rana R McKay, Mingji...> ;Journal of Clinical Oncology. 2023 Jul 20
8 citations
Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus...
Felice Crocetto, Matteo Ferro, Carlo Buonerba, Luca Bardi, Pasquale Dolce, Luca Scafuri, Benito Fabio Mirto, Antonio Verde, Antonella Sciarra, Biagio Barone, Armando C...> ;Critical Reviews in Oncology/hematology. 2023 Aug 1
6 citations
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
Emanuele Crupi, Tiago Costa de Padua, Laura Marandino, Daniele Raggi, Lars Dyrskjøt, Philippe E Spiess, Guru P Sonpavde, Ashish M Kamat, Andrea Necchi> ;European Urology Oncology. 2024 Feb 1
Precision Medicine to Treat Urothelial Carcinoma-The Way Forward.
Carvy Floyd Luceno, Won Jin Jeon, Ravand Samaeekia, John Shin, Guru P Sonpavde> ;Cancers. 2023 Jun 1
1 citations
Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Avani M Singh, Jose A Guevara-Patino, Xuefeng Wang, Roger Li, Guru Sonpavde, Rohit K Jain> ;Biodrugs. 2023 Jul 1
5 citations
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Matteo Ferro, Felice Crocetto, Sabin Tataru, Biagio Barone, Pasquale Dolce, Giuseppe Lucarelli, Guru Sonpavde, Gennaro Musi, Alessandro Antonelli, Alessandro Veccia, D...> ;Clinical Genitourinary Cancer. 2023 Oct 1
Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Kyle M Rose, Heather L Huelster, Joshua J Meeks, Bishoy M Faltas, Guru P Sonpavde, Seth P Lerner, Jeffrey S Ross, Philippe E Spiess, G Daniel Grass, Rohit K Jain, Ashi...> ;Nature Reviews. Urology. 2023 Jul 1
2 citations
Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
Alicia K Morgans, Matthew D Galsky, Phoebe Wright, Zsolt Hepp, Nancy Chang, Candice L Willmon, Steve Sesterhenn, Yutong Liu, Guru P Sonpavde> ;Urologic Oncology. 2023 Aug 1
5 citations
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Kyle M Rose, Heather L Huelster, Joshua J Meeks, Guru P Sonpavde, Seth P Lerner, Jeffrey S Ross, Philippe E Spiess, G Daniel Grass, Rohit K Jain, Ashish M Kamat, Aram ...> ;Nature Reviews. Urology. 2023 Jul 1
8 citations
Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach.
Suryadipto Sarkar, Kong Min, Waleed Ikram, Ryan W Tatton, Irbaz B Riaz, Alvin C Silva, Alan H Bryce, Cassandra Moore, Thai H Ho, Guru Sonpavde, Haidar M Abdul-Muhsin, ...> ;Cancers. 2023 Mar 8
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma.
Rohit K Jain, Avani M Singh, Xuefeng Wang, José A Guevara-Patiño, Guru Sonpavde> ;Expert Opinion on Emerging Drugs. 2023 Mar 1
5 citations
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Zachary Quinn, Benjamin Leiby, Guru Sonpavde, Atish D Choudhury, Christopher Sweeney, David Einstein, Russell Szmulewitz, Oliver Sartor, Karen Knudsen, Eddy Shih-Hsin ...> ;Clinical Cancer Research. 2023 Jan 4
4 citations
Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint.
Abhishek Tripathi, Guru P Sonpavde, MacDougall, K.> ;Drugs. 2022 Nov 1
4 citations
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
Hina Shah, Praful Ravi, Guru Sonpavde, Heather Jacene> ;Expert Review of Anticancer Therapy. 2022 Nov 1
34 citations
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W Akl, Pier Vitale Nuzzo, Tarek H Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Hab...> ;Cancer Cell. 2022 Oct 10
Join now to see all

Journal Articles

Development and Validation of a Prognostic Model for Overall Survival in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer
G Sonpavde, C S Higano, T M Beer, Annals of Oncology
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration
Richard S Foster, Lawrence H Einhorn, Christopher J Sweeney, Guru Sonpavde, Costantine Albany, Chandra K Flack, The Journal of Urology
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.
Sonpavde G, Pond GR, Fougeray R, Bellmunt J., BJU Int, 2014

Lectures

5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.
2019 ASCO Annual Meeting - 6/1/2019
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) Â± BMS-986205 in cisplatin-eligible muscle invasive bladder ...
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Practice-changing and Practice-impacting Genitourinary Oncology Highlights From the ESMO Congress 2023October 2023
Genitourinary Oncology Highlights From the ASCO Annual Conference 2023June 2023
ASCO GU 2023: Practice Changing, Practice Reaffirming, Practice Informing and Emerging AdvancesFebruary 2023
GU Updates Abound at ASCO 2021June 2021
Cancer treatment: is a clinical trial right for youMarch 2019
Immunotherapy for cancer therapy: What you need to knowJanuary 2019
Join now to see all

Press Mentions

New Approaches in the Bladder-Sparing ParadigmMarch 20th, 2023
Immune Checkpoint Inhibitors for Patients Living with HIV: Safe and Effective in Metastatic NSCLCNovember 11th, 2022
GU Updates Abound at ASCO 2021June 14th, 2021
Join now to see all